Repurposing mitochondria-targeted therapeutics for kidney diseases

Area of Science:

• Nephrology
• Mitochondrial Biology
• Pharmacology

Background:

• Kidneys are highly metabolically active organs requiring significant adenosine triphosphate (ATP) for function.
• Proximal tubule cells are rich in mitochondria to meet high energy demands.
• Mitochondrial dysfunction is a key factor in the development and progression of kidney diseases, leading to cell injury and fibrosis.

Purpose of the Study:

• To provide an overview of mitochondrial dysfunction in kidney injury and disease.
• To highlight mitochondria-targeted therapeutics with repurposing potential for kidney diseases.
• To discuss the advantages of drug repurposing for kidney disease treatment.

Main Methods:

• Literature review on mitochondrial dysfunction in renal pathology.
• Analysis of current research on mitochondria-targeted therapies.
• Evaluation of drug repurposing strategies for kidney diseases.

Main Results:

• Mitochondrial dysfunction contributes to redox imbalance, impaired bioenergetics, oxidative stress, and inflammation in kidneys.
• Several mitochondria-targeted agents show potential for treating kidney conditions.
• Drug repurposing offers advantages like reduced cost and development time compared to novel drug discovery.

Conclusions:

• Mitochondrial dysfunction is a critical therapeutic target in kidney disease.
• Repurposing existing drugs offers a viable and efficient approach to develop new treatments for kidney disorders.
• Targeting mitochondria holds promise for restoring kidney function and promoting renal recovery.